



**Angiogenesis, Exudation, and Degeneration 2025
February 8, 2025**

Program Directors: Philip J. Rosenfeld, Harry W. Flynn, Jr., and Thomas A. Albini

PROGRAM

Subject to Change

Saturday, February 08, 2025

7:50 am Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, Harry W. Flynn, Jr., MD, and
Thomas A. Albini

Session I: OCTomics

Moderators: Giovanni Gregori, Philip J. Rosenfeld, and Omer Trivizki

Panelists: K. Bailey Freund, James G. Fujimoto, Nadia K. Waheed, Alessandro Berni, Sara Beqiri, Roy Schwartz, David Sarraf, Seung-Young Yu

8:00 Novel Findings from Innovative High-Res and Wide-Field OCT Devices
K. Bailey Freund

**8:10 Topographic Measurement of the Bruch's Membrane/RPE Complex in
Normal Aging and Age-Related Macular Degeneration Using High-
Resolution Volumetric OCT**
James G. Fujimoto

**8:20 Vista 2.0 Longitudinal Changes in Choriocapillaris Flow Speeds in Patients
with Dry AMD**
Nadia K. Waheed

**8:30 Updated Guidelines for Imaging the Choriocapillaris in AMD Using Swept-
Source OCT Angiography**
Alessandro Berni

**8:40 Choriocapillaris Perfusion and the Appearance of Choroidal
Hypertransmission Defects in AMD**
Sara Beqiri

8:50 **Genetic Distinctions Between Reticular Pseudodrusen and Drusen: Insights from a Genome-Wide Association Study**
Roy Schwartz

9:00 **Drusen Distribution and Morphology with En Face OCT**
David Sarraf

9:10 **Changes in Drusen Parameters in a Korean Patient Cohort**
Seung-Young Yu

Session II: Imaging of Non-Exudative AMD

Moderators: Philip J. Rosenfeld, Jaclyn L. Kovach, and Zohar Yehoshua

Panelists: Giovanni Staurenghi, Giuseppe Querques, Ursula Schmidt-Erfurth, Peter K. Kaiser, Ruikang Wang, Marc Steffen Schmitz-Valckenberg, Hasenin Al-Kharsan, Monika Fleckenstein, Karl Csaky

9:20 **Differential Diagnosis of Macular Atrophy**
Giovanni Staurenghi

9:30 **Progression Patterns in Foveal-Sparing GA Secondary to AMD with Double Layer Sign**
Giuseppe Querques

9:40 **AI-Based Biomarkers for GA Progression**
Ursula Schmidt-Erfurth

9:50 **Optical Coherence Tomography to Function (OCT Fx) Delphi Study: Global Consensus on the Use of the Ellipsoid Zone as a Dry AMD Clinical Trial Endpoint that Connects Structure to Function**
Peter K. Kaiser

10:00 **Alternative Strategies to Assess Photoreceptor Integrity in the Investigation of AMD**
Ruikang Wang

10:10 **Design and Enrollment of Subjects with High-Risk and Early Atrophic Features in the Multicenter, Prospective Observational Study of the Progression of Intermediate Age-Related Macular Degeneration - The HONU Study**
Marc Steffen Schmitz-Valckenberg

10:20 **Automated Segmentation of Geographic Atrophy Using Optical Coherence Tomography: A Real-World Approach**
Hasenin Al-Kharsan

10:30 **Geographic Atrophy: Association of Lesion Location and Functional Parameters with Vision-Related Quality of Life**
Monika Fleckenstein

10:40 **Use of Virtual Reality Metrics as An Outcome Measures in Clinical Trials for Geographic Atrophy**
Karl Csaky

Session III: Emerging Therapies for Non-Exudative AMD

Moderators: Raquel Goldhardt, Maura Di Nicola, Philip J. Rosenfeld

Panelists: Omer Trivizki, Mario Saravia, Christine A. Curcio, Michael S. Ip, David R. Lally, Eleonora M. Lad, David S. Boyer, Charles C. Wykoff, Glenn J. Jaffe

10:50 **The Association Between MRI-Assessed Perfusion and The Severity And Symmetry of AMD**
Omer Trivizki

11:00 **Ophthalmic Artery Angioplasty for Geographic Artery: Results of A Pilot Device Study**
Mario Saravia

11:10 **Histologic Insights into Autofluorescence Signatures and Neurodegeneration in Geographic Atrophy**
Christine A. Curcio

11:20 **Evaluation of Junctional Hyperautofluorescence in GA Lesions: Results From the AVD-104 Phase 1 Clinical Trial**
Michael S. Ip

11:25 **Baseline Quantitative Ellipsoid Zone (EZ) Integrity Parameters in ReCLAIM-2: Impact on Photoreceptor Loss and Low Luminance BCVA in Dry AMD**
David R. Lally

11:35 **Impact of ANX007 on the Central Ellipsoid Zone (EZ) and Visual Function in the Phase 2 ARCHER GA Study**
Eleonora M. Lad

11:45 **Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration**
David S. Boyer

11:55 **Efficacy and Safety of Complement Factor B Antisense, IONIS-FB-LRx, in Geographic Atrophy due to Age-Related Macular Degeneration: Results of the Phase 2 GOLDEN Study**
Charles C. Wykoff

12:05 Imaging Biomarkers in the Lumithera Trial of Photobiomodulation to Treat Dry AMD
Glenn J. Jaffe

Session IV: FDA-Approved Complement inhibitors for the Treatment of GA

Moderators: Thomas A. Albini, Omer Trivizki, and Philip J. Rosenfeld

Panelists: Nathan C. Steinle, Dilsher Dhoot, David S. Boyer, Mathew MacCumber, Mengxi Shen

12:15 Analysis of AREDS Vitamins on Geographic Atrophy Growth: Insights from the OAKS and DERBY Studies
Nathan C. Steinle

12:25 Treatment Response in Sham Eyes Initiating Pegcetacoplan Treatment in GA due to AMD at 12 Months in the GALE Extension
Dilsher Dhoot

12:35 Treatment of Subfoveal Geographic Atrophy with Pegcetacoplan
David S. Boyer

12:45 Real World Practice Patterns and Adverse Events of Complement Inhibition for Geographic Atrophy
Mathew MacCumber

12:55 Real-World Efficacy of Intravitreal Pegcetacoplan in AMD
Mengxi Shen

1:05 Real-World Safety of Intravitreal Pegcetacoplan in AMD
Philip J. Rosenfeld

1:15 Panel Discussion: Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD
David S. Boyer, Nadia K. Waheed, Michael S. Ip, Ursula Schmidt-Erfurth, Karl G. Csaky, Usha Chakravarthy, Arshad M. Khanani, David R. Lally, Justis P. Ehlers, Glenn J. Jaffe, Mathew McCumber, Mengxi Shen, Omer Trivizki, Dilsher Dhoot, Lawrence Singerman, Nathan C. Steinle, Charles C. Wykoff, Giuseppe Querques, Thomas A. Albini, Philip J. Rosenfeld

Session V: Imaging and Emerging Therapies for Exudative AMD

Moderators: Luis J. Haddock, Lawrence Singerman, and Philip J. Rosenfeld

Panelists: David M. Brown, Usha Chakravarthy, Michael Singer, Xiaodong Sun, Charles C. Wykoff, Dante Pieramici, Carl Danzig, Carl D. Regillo, Jeffrey S. Heier, Anat Loewenstein, Roger A. Goldberg

- 1:35 **Why Do Some Eyes Require More Frequent Injections? The Case for Drug Clearance**
David M. Brown
- 1:45 **Final Analysis of the Phase 2 BETTER Trial: Evaluating Intravitreal ISTH0036, a Selective TGF- β 2 Blocking Antisense Therapy in Neovascular AMD and DME**
Usha Chakravarthy
- 1:55 **Subcutaneous Migaldendranib (MGB) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: 9 Month Results of Chronic Dose Phase 2 Study**
Michael Singer
- 2:05 **Gene Therapy for Neovascular Age-Related Macular Degeneration by Subretinal Delivery of LX102: 12-Month Results from A Phase 1 Study**
Xiaodong Sun
- 2:10 **Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular AMD: 52-Week Primary Efficacy and Safety Results from The Phase 2 LUNA Study**
Charles C. Wykoff
- 2:20 **Phase 2 PRISM Clinical Trial Evaluating 4D-150 in Adults with Neovascular AMD**
Dante Pieramici
- 2:30 **OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMD**
Carl Danzig
- 2:35 **EYP-1901 for Retinal Exudative Diseases: Phase 2 Davio 2 nAMD End-of-Study Results and Phase 2 Verona DME Results**
Carl D. Regillo
- 2:45 **Longitudinal Pivotal Home OCT Trial to Compare Visualization of nvAMD Biomarkers with In-Office OCT**
Jeffrey S. Heier
- 2:55 **Cross-Sectional Pivotal Home OCT Trial to Compare Performance of AI-Enabled Algorithms with Human Graders in nvAMD**
Anat Loewenstein
- 3:05 **Phase 2b CLS-AX ODYSSEY Trial Results**
Roger A. Goldberg

Session VI: FDA-Approved Therapies for Exudative AMD and Retinal Vascular Diseases

Moderators: Janet L. Davis, Basil Williams, and Thomas A. Albin

Panelists: Gemmy Cheung Chui Ming, Veeral Sheth, Arshad M. Khanani, John A. Wells, III, Tien Y. Wong, W. Lloyd Clark, Diana V. Do, Domenico Lepore

- 3:15 **Faricimab for PCV: The SALWEEN Study**
Gemmy Cheung Chui Ming
- 3:25 **Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US**
Veeral Sheth
- 3:35 **Real-World Efficacy and Safety of Faricimab in nAMD: First Time Three-Year Results of the TRUCKEE Study**
Arshad M. Khanani
- 3:45 **Faricimab in DME: Results From the RHONE-X Long-Term Extension Trial**
John A. Wells, III
- 3:55 **Three-Year Outcomes of Aflibercept 8mg in nAMD: Safety and Efficacy Results from the PULSAR Extension study**
Tien Y. Wong
- 4:05 **Three-Year Outcomes of Aflibercept 8mg in Diabetic Macular Edema: Safety and Efficacy Results from the PHOTON Extension Study**
W. Lloyd Clark
- 4:15 **Differential Anatomic Response to Aflibercept 8 mg versus 2 mg in DME Patients Who Met Shortening Criteria in the Phase 2/3 PHOTON Trial**
Diana V. Do
- 4:25 **3-year Outcomes in Children with ROP Treated with Intravitreal Aflibercept vs Laser in the Randomized FIREFLEYE Study**
Domenico Lepore

Session VII: Diabetic Retinopathy and Retinal Vascular Diseases

Moderators: Harry W. Flynn, Jr., Justin H. Townsend, and William E. Smiddy

Panelists: Toshinori Murata, Jennifer K. Sun, David Eichenbaum, Srinivas R. Sadda, Quan Dong Nguyen, Mark R. Barakat, Justis P. Ehlers, Arshad M. Khanani, Richard P. Gale, Martin Friedlander, Thomas A. Albin

- 4:35 **AI-Assisted Detection of Leakage and Microaneurysms in OCT-Angiography**
Toshinori Murata

- 4:45 **Influence of Age on Anti-VEGF Treatment Response in DME**
Jennifer K. Sun
- 4:55 **First Time Analysis of Fellow Eyes with DME in the PAGODA Port Delivery System Study**
David Eichenbaum
- 5:05 **Predicting Treatment Response and Anatomic Outcomes Using Generative AI in Diabetic Retinopathy**
SriniVas R. Sadda
- 5:15 **BI 764524: Therapy in Development for Diabetic Macular Ischemia**
Quan Dong Nguyen
- 5:20 **Phase 1 Results from Intravitreal Axitinib Implant (OTX-TKI) for the Treatment of Non-Proliferative Diabetic Retinopathy**
Mark R. Barakat
- 5:25 **Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Implant (OTX-TKI) from the Helios Clinical Trial for Diabetic Retinopathy**
Justis P. Ehlers
- 5:30 **Suprachoroidal Delivery of ABBV-RGX-314 for Diabetic Retinopathy: Expanded Study Results from the Phase II ALTITUDE® Study**
Arshad M. Khanani
- 5:40 **Aflibercept 8mg in RVO: Primary Endpoint Results from the QUASAR Study**
Richard P. Gale
- 5:50 **What's New with MacTel2?**
Martin Friedlander
- 6:00 **Intraocular Drug Delivery Lasting Over a Decade: Ciliary Neurotrophic Factor (CNTF) Secreted by Encapsulated Cell Technology Implants (NT-501) Treating Patients with Retinal Degenerative Disorders**
Thomas A. Albini

Session VIII: Inherited Retinal Degenerations

Moderators: Byron L. Lam, Sander R. Dubovy, Ninel Z. Gregori

Panelists: Robert Bhisitkul, Allen C. Ho, Quan D. Nguyen, Baruch Kuppermann

- 6:10 **Safety and Efficacy Outcomes from A Single Dose Ascending Study of VP-001 in Retinitis Pigmentosa Type 11 (RP11) Patients**
Robert Bhisitkul

- 6:15 First-in-Human Clinical Trial to Evaluate Safety and Exploratory Efficacy of Photoreceptor Regeneration Treatment with EA-2353 in Retinitis Pigmentosa: Final Month 12 Results**
Byron L. Lam
- 6:25 Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results from a Long-Term Follow-Up Study (REMAIN)**
Allen C. Ho
- 6:35 Tinlarebant for Adolescent Stargardt Disease**
Quan Dong Nguyen
- 6:45 Gildeuretinol Phase 2 Studies in Stargardt Disease**
Baruch Kuppermann
- 6:55 Post-Program Test and Closing Remarks**
- 7:00 Meeting Adjourns**